Schaaf Drugs, LLC

Schaaf Drugs, LLC, operating under the doing-business-as name Heartlight Pharmacy Services, is a for-profit limited liability company based in Lima, Ohio, that has established itself as a specialized supplier of radiopharmaceutical drugs and nuclear medicine products to the U.S. Department of Veterans Affairs. Since registering in the System for Award Management in 2010, the company has developed deep expertise in manufacturing and distributing unit-dose radiopharmaceuticals and radioactive isotopes essential for diagnostic imaging and treatment procedures. Heartlight Pharmacy Services has become a critical and exclusive prime contractor for radiopharmaceutical provision to the VA's Veterans Integrated Service Network 10 (VISN 10), which serves Ohio and Indiana, supplying nuclear medicine supplies that support the VA's healthcare delivery system for veterans across the region.

Through its federal contract awards, Heartlight Pharmacy Services has consistently delivered a comprehensive range of specialized radiopharmaceutical products and services to the Department of Veterans Affairs, specifically to Veterans Integrated Service Network 10. The company's delivery orders have included provision of critical medical isotopes such as Technetium-99m compounds (including sulfur colloid, MDP, Mebrofenin, MAG-3, Tetrofosmin, and MAA), Pentetreotide, Thallium-201, and Iodine-123, all of which are fundamental to diagnostic imaging and nuclear medicine treatment for veterans. Beyond product delivery, Heartlight Pharmacy Services has provided associated nuclear medicine services including quality control testing, labeling, invoicing, recordkeeping in compliance with Nuclear Regulatory Commission and Department of Transportation requirements, and routine delivery services with emergency and stat order capabilities. All contract awards have been to Heartlight Pharmacy Services as the prime contractor with no identified subcontractors, and none of the awards utilized set-aside designations, reflecting the specialized and niche nature of the radiopharmaceutical market. Recent delivery orders include a $680,646.30 award for Year 4, Option Year 3 radiopharmaceutical drugs with a completion date of November 22, 2026, and multiple prior years of consistent awards ranging from approximately $24,000 to $3.7 million, demonstrating the VA's sustained reliance on the company's specialized pharmaceutical expertise.

Schaaf Drugs, LLC currently holds five Indefinite Delivery Contracts with the Department of Veterans Affairs Veterans Integrated Service Network 10, collectively representing substantial procurement authority for radiopharmaceutical products and radioactive isotopes. The largest IDC, awarded on October 1, 2021, carries a ceiling value of $3,888,886.25 with an ultimate completion date of September 30, 2026, and specifically supports radiopharmaceutical provision to the Dayton VA Medical Center in Lima, Ohio, procuring unit-dose radiopharmaceuticals and delivery services for diagnostic imaging and cancer treatment procedures. A second major IDC awarded November 23, 2022, has a ceiling value of $3,249,071.28 with performance through November 22, 2027, for the provision of radiopharmaceutical drugs. An additional IDC awarded October 1, 2022, carries a ceiling value of $339,599.00 with performance through September 30, 2027, for radioactive isotope provision to support nuclear medicine services, with deliveries made from Lima, Ohio, and Fort Wayne, Indiana. A fourth IDC with a ceiling value of $604,977.60 and performance period through January 5, 2028, awarded on January 6, 2023, provides for radiopharmaceutical drugs and radioactive isotopes to VA medical facilities throughout the VISN 10 region, including the Chalmers P. Wylie VA Ambulatory Care Center in Columbus, Ohio, with unit-dose deliveries made once or twice daily alongside emergency and stat order capabilities. The fifth IDC, with a ceiling value of $604,961.69 and the same January 5, 2028 completion date, was established to address a procurement gap by including the PYP-TC99M Atrial Amyloidosis diagnostic radiopharmaceutical that was inadvertently omitted from the original price schedule. All five IDCs are firm fixed-price contracts without set-aside designations, underscore the VA's long-term commitment to Heartlight Pharmacy Services as its exclusive radiopharmaceutical provider, and have supported numerous delivery orders throughout their performance periods.

Small business with 8 yrs. of experience providing radiopharmaceuticals to doctors, clinics and hospitals. www.heartlightpharmacy.com